All In Biotech

Investigational drug · Phase 2

OPM-101

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Melanoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "OPM-101"

First trial start

2025

Sep 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "OPM-101", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Melanoma

Approved drugs for the same conditions: Melanoma · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "OPM-101" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Advanced Melanoma

  • LBL-024Phase 311 trials

    Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma

  • EIK1001Phase 33 trials

    Eikon Therapeutics · Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous)

  • BrenetafuspIMC-F106CPhase 32 trials

    Immunocore Ltd · Select Advanced Solid Tumors, Advanced Melanoma

  • RO7198457Autogene CevumeranPhase 24 trials

    Roche (Genentech) · Colorectal Cancer Stage II, Colorectal Cancer Stage III, Adenocarcinoma, Pancreatic Ductal

  • T3011Phase 24 trials

    Shanghai Pharmaceuticals Holding Co., Ltd · Advanced Solid Tumors, Nonmuscle-invasive Bladder Cancer, Solid Tumor

  • LM103 TILsPhase 22 trials

    Suzhou BlueHorse Therapeutics Co., Ltd. · Advanced Melanoma, Non-Small Cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.